17 October 2022 - This guidance provides recommendations to sponsors regarding considerations for tissue agnostic drug development in oncology. 

For the purpose of this guidance, the term tissue agnostic oncology drug refers to a drug that targets a specific molecular alteration(s) across multiple cancer types as defined, for example by organ, tissue, or tumour type.

Read FDA draft guidance for industry